Solara Active Pharma Sciences Limited

BSE: 541540 NSE: SOLARA
Solara Active Pharma Sciences Limited - pharma in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH2017PLC291636 Incorporated 23 February 2017 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: SOLARA · BSE: 541540 Public Limited Company pharma
Data last updated
Market Cap
₹3,145 Cr
SOLARA · NSE
Share Price
₹648.05
-0.99% today
Revenue
₹1,369 Cr
FY 2025-26 · +6.6% YoY
EBITDA
₹181 Cr
Margin 13.2%
Net Profit
−₹1.52 Cr
FY 2025-26 · -381.5% YoY
P/E (TTM)
67.1x
P/B 2.2x
Debt / Equity
0.63
Interest cover 116.7x
Authorised capital
₹120 Cr
Registered with MCA

About Solara Active Pharma Sciences Limited

Data last updated:

Solara Active Pharma Sciences Limited is a public limited company based in Thane, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 23 February 2017 and has been in existence for over 9 years.

Its director Arun Kumar Pillai is #551 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH2017PLC291636. Its GSTIN is 27AAYCS2093N2ZB (Maharashtra). The company holds 8 GST registrations, of which 6 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 541540 and NSE: SOLARA.

The company has an authorised share capital of ₹120 Cr and a paid-up capital of ₹47.98 Cr. It was formerly known as Ssl Pharma Sciences Limited. It is led by directors including Sandeep Shashikantha Rao (Managing Director) and Sanjeevi Mohanraj (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,368.98 Cr, a growth of 6.6% compared to the previous year. For the same year it recorded a net loss of ₹1.52 Cr (net margin -0.1%) and EBITDA of ₹180.86 Cr (EBITDA margin 13.2%). The net worth stands at ₹1,252.88 Cr (up 14.5% YoY). Total assets are valued at ₹1,995.58 Cr (up 2.2% YoY).

The company has about 1,656 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Solara Active Pharma Sciences. As per MCA filings, the company has open charges of ₹507.5 Cr and satisfied charges of ₹2,480.69 Cr on record. Court records list 37 cases involving the company, including 19 filed by the company and 18 filed against it; 14 cases are pending. The company has 47 deals on record (37 market trades, 4 secondary share transfers, 3 funding rounds), with disclosed funding of ₹460 Cr; the latest was in July 2026. The company has 3 MSME Form 1 returns on record between 2019 and 2022, listing 43 overdue payments to 12 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website solara.co.in.

Company details

CIN L24230MH2017PLC291636
Registration Number 291636
Incorporation Date 23 February 2017
ROC Mumbai
Listing Status Listed - Listed on NSE (SOLARA); Listed on BSE (541540)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Solara Active Pharma Sciences has one previous CIN (Corporate Identification Number): U24230MH2017PLC291636. The current CIN is L24230MH2017PLC291636, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230MH2017PLC291636Current
U24230MH2017PLC291636Previous
Key People
Sandeep Shashikantha Rao Managing Director Sanjeevi Mohanraj Whole-Time Director Ramakrishnan Rajagopal Director

Recognitions & Rankings of Solara Active Pharma Sciences

India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Solara Active Pharma Sciences Limited's registered office is in Thane, Maharashtra. Its website is solara.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    solara.co.in
  • Social Media
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Solara Active Pharma Sciences Limited, buy the company report.

Comprehensive company report
Solara Active Pharma Sciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Solara Active Pharma Sciences operates one associated brand: Solara Active Pharma Sciences. Each brand links to its own profile.

BrandDescriptionWebsite
Solara Active Pharma Sciences
APIs and intermediates are manufactured for therapeutic categories.solara.co.in

Business activity

The main business activity of Solara Active Pharma Sciences is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Solara Active Pharma Sciences Limited, buy the company report.

Financials of Solara Active Pharma Sciences Limited

FY 2025-26 filings available

Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr (up 6.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,369 Cr
+6.6% YoY
EBITDA
₹181 Cr
-12.3% YoY
Profit After Tax
−₹1.52 Cr
-381.5% YoY
Net Worth
₹1,253 Cr
+14.5% YoY
Total Assets
₹1,996 Cr
+2.2% YoY
Total Debt
₹687 Cr
-13.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Balance sheet
Total assets1,9961,9522,0022,5652,6252,2791,888
Net worth1,2531,0949341,5001,5251,5891,086
Total debt6877961,0121,0131,037621722
Cash & bank50.344.118.608.8947.2519956.78
Net working capital518449452853919723419
Cash flow
Cash from operations153213109156(242)155242
Cash from investing(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Cash from financing(53.55)(180)(106)(113)33492.4996.98
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.542.695.550.000.490.985.951.49
EBITDA72.3461.9757.6630.5934.7357.0245.3757.68
EBITDA margin+17.3%+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest17.7821.6427.5722.4520.8323.9029.1226.54
Profit before tax28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
Tax0.000.000.000.000.000.000.000.00
Net profit28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
EPS (₹)5.923.522.20(3.98)(2.36)2.46(0.93)2.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Balance sheet
Total assets1,9461,9512,0032,5652,6252,2791,889
Net worth1,2551,0969371,5031,5271,5931,091
Total debt6377961,0121,0131,037621722
Cash & bank4.163.978.488.7147.1419856.58
Net working capital478455447861927727424
Cash flow
Cash from operations153213111156(242)154242
Cash from investing(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Cash from financing(103)(180)(107)(113)33492.5097.01
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.231.925.280.000.490.985.951.49
Total expenses345320330318279262230243
EBITDA72.3862.0157.5530.6034.7557.0342.5957.69
EBITDA margin+17.3%+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest16.3620.2327.0622.4520.8323.9029.1226.54
Profit before tax29.6116.999.73(17.42)(10.08)10.53(4.88)8.10
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.542.695.550.000.490.985.951.49
EBITDA72.3461.9757.6630.5934.7357.0245.3757.68
EBITDA margin+17.3%+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest17.7821.6427.5722.4520.8323.9029.1226.54
Profit before tax28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
Tax0.000.000.000.000.000.000.000.00
Net profit28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
EPS (₹)5.923.522.20(3.98)(2.36)2.46(0.93)2.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
Other income6.168.325.3722.5520.0228.7727.52
Total expenses1,1881,0771,5741,3101,1921,2311,062
Employee cost224215247229236229204
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Depreciation99.6899.2510311111210994.16
Interest94.7511510590.0675.2884.4877.89
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Tax0.000.0078.54(22.57)(32.81)0.150.39
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2081,0548981,4641,4891,553963
Shareholders' funds (net worth)1,2531,0949341,5001,5251,5891,086
Minority interest2.672.672.672.242.314.244.29
Secured loans6657399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6877961,0121,0131,037621722
Total liabilities1,9961,9522,0022,5652,6252,2791,888
Assets
Gross block2,0381,8991,8791,8951,7791,7021,611
Net block1,2381,1931,2681,3641,3561,3821,397
Capital work in progress20528025623823987.9840.47
Investments4.621.701.701.700.420.420.32
Inventories318318360558576295280
Sundry debtors439327349537490484227
Cash & bank balances50.344.118.608.8947.2519956.78
Loans & advances48.1780.1583.9383.5712780.25109
Total current assets8557298011,1881,2391,058672
Total current liabilities337280349335320335253
Net working capital518449452853919723419
Total assets1,9961,9522,0022,5652,6252,2791,888
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.958.448.7346.3819856.0475.72
Net cash from operating activities153213109156(242)155242
Net cash from investing activities(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Net cash from financing activities(53.55)(180)(106)(113)33492.4996.98
Net change in cash0.53(4.49)(0.29)(37.65)(151)142(19.68)
Closing cash50.344.118.608.8947.2519956.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA growth-12.3%+172.3%-313.1%+75.1%-80.2%+48.7%-
PBT growth-+9998.0%-989.7%+50.8%-+92.8%+91.6%
Net income growth-381.5%+100.1%-1778.1%+59.7%-124.5%+91.3%-
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.6%+39.2%--19.8%-28.9%+89.3%-
Profitability & leverage
Net income margin-0.5%+0.0%-44.0%-1.5%-4.6%+13.7%+8.7%
Return on capital employed0.0%+5.4%0.0%+1.7%-0.7%+14.7%+11.1%
Return on net worth0.0%+0.1%0.0%-1.5%-3.7%+16.6%+11.2%
Debt / equity0.630.890.830.680.530.500.62
Long-term debt / equity0.110.120.150.180.150.150.23
Interest cover116.72107.27-27.04396.91-210.0430.4847.13
Efficiency & per share
Fixed asset turnover0.700.680.680.790.730.980.90
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.802.912.812.614.555.13
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)281.48271.86259.42416.73423.57442.12368.69
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.231.925.280.000.490.985.951.49
Total expenses345320330318279262230243
EBITDA72.3862.0157.5530.6034.7557.0342.5957.69
EBITDA margin+17.3%+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest16.3620.2327.0622.4520.8323.9029.1226.54
Profit before tax29.6116.999.73(17.42)(10.08)10.53(4.88)8.10
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
Other income5.899.145.3722.1418.7628.4127.51
Total expenses1,1881,0801,5741,3101,1911,2321,065
Employee cost224215247228234228202
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Depreciation99.6899.2510311111210893.67
Interest94.2411510690.0675.2784.4777.88
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Tax0.000.0078.54(22.57)(33.10)0.000.00
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2111,0569011,4671,4911,557968
Shareholders' funds (net worth)1,2551,0969371,5031,5271,5931,091
Secured loans6157399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6377961,0121,0131,037621722
Total liabilities1,9461,9512,0032,5652,6252,2791,889
Assets
Gross block2,0311,8921,9331,8711,7641,6781,587
Net block1,2311,1871,2611,3421,3341,3591,374
Capital work in progress20528025623823987.7240.21
Investments1.631.7014.2516.0514.7718.1318.03
Inventories318318360558576295280
Sundry debtors439327351540490484230
Cash & bank balances4.163.978.488.7147.1419856.58
Loans & advances47.7980.1671.2584.4212880.83109
Total current assets8097297911,1911,2401,058675
Total current liabilities331274344330312331251
Net working capital478455447861927727424
Total assets1,9461,9512,0032,5652,6252,2791,889
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.818.328.5546.2719855.8475.62
Net cash from operating activities153213111156(242)154242
Net cash from investing activities(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Net cash from financing activities(103)(180)(107)(113)33492.5097.01
Net change in cash0.19(4.51)(0.23)(37.72)(151)142(19.78)
Closing cash4.163.978.488.7147.1419856.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA growth-11.3%+171.6%-312.4%+74.4%-80.1%+50.2%-
PBT growth-570.4%+99.8%-990.5%+51.2%-+96.4%+85.4%
Net income growth-25.0%+99.7%-1775.1%+59.9%-124.8%+94.5%-
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.5%+38.4%--19.5%-28.9%+87.3%-
Profitability & leverage
Net income margin-0.5%-0.1%-44.0%-1.5%-4.6%+13.7%+8.5%
Return on capital employed0.0%0.0%0.0%+1.7%-0.7%+14.7%+11.0%
Return on net worth0.0%0.0%0.0%-1.5%-3.8%+16.5%+11.0%
Debt / equity0.610.890.830.680.530.500.61
Long-term debt / equity0.090.120.150.180.150.150.23
Interest cover116.19109.77-27.33389.20-214.1430.4947.82
Efficiency & per share
Fixed asset turnover0.700.670.680.790.740.990.91
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.792.892.812.614.535.08
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)282.06272.35260.39417.54424.18443.30370.50

To see the full year-wise statements and ratios of Solara Active Pharma Sciences Limited, buy the company report.

Board of directors of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences has 8 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ramakrishnan Rajagopal
Also directs: Synthix Global Pharma Solutions Limited, Multivision Business Solutions Private Limited, Murudeshwar Decor Private Limited
Director11 Apr 20188 Years 6 MonthsCurrent
Kausalya Santhanam
Also directs: Strides Pharma Science Limited, Synthix Global Pharma Solutions Limited, Right Way Nutrition LLP and 1 more
Director11 Apr 20188 Years 6 MonthsCurrent
Arun Kumar Pillai
Also directs: Chayadeep Ventures LLP, Agnus Capital LLP, Karuna Group LLP and 3 more
Director04 Aug 20215 Years 3 MonthsCurrent
Sandeep Shashikantha RaoManaging Director21 Feb 20251 Years 8 MonthsCurrent
Manish Gupta
Also directs: Synthix Global Pharma Solutions Limited, Jagson Pal Pharmaceuticals Limited., Intron Life Sciences Private Limited
Director22 Jul 20242 Years 3 MonthsCurrent
Rajendra Kumar Srivastava
Also directs: Latticed Advisors LLP, Happiest Minds Technologies Limited, Faculty World Private Limited
Director14 Nov 20232 Years 11 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Auditor

Solara Active Pharma Sciences Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & Sells LLPFY 2025117366W/W-100018

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 41.90%, foreign institutional investors hold 11.50%, domestic institutional investors hold 3.80% and retail and other public shareholders hold 42.80%.

Promoters: 41.90%DII (Domestic Institutional): 3.80%FII (Foreign Institutional): 11.50%Retail & Others: 42.80%
Sep 2026
QUARTER
41.90% Promoters
3.80% DII (Domestic Institutional)
11.50% FII (Foreign Institutional)
42.80% Retail & Others
Promoter holding - history
Now 41.90% · Sep 2026High 42.00% · Dec 2025Low 41.90% · Sep 2026
40%40.8%41.5%42.3%43%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 42.00%Mar 2026: 42.00%Jun 2026: 42.00%Sep 2026: 41.90%42.00%41.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters41.90%42.00%42.00%42.00%
Public58.10%58.00%58.00%58.00%

Charges & borrowings

Open charges
₹507.5 Cr
Satisfied charges
₹2,480.69 Cr
Breakdown by lending institutions
Others₹367.50 Cr
Yes Bank Limited₹140.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Jan 2025101045752Others₹75 CrOpen
28 Sep 2022100614350Yes Bank Limited₹75 CrOpen
28 Sep 2022100614480Yes Bank Limited₹65 CrOpen
22 Nov 2021100510551Others₹150 CrOpen
30 May 2019100268311Others₹142.5 CrOpen

To see the full charge records of Solara Active Pharma Sciences Limited, buy the company report.

Total charge records: 26 View all charges

Deals & funding

Solara Active Pharma Sciences Limited has 47 deals on record (37 market trades, 4 secondary share transfers, 3 funding rounds), with disclosed funding of ₹460 Cr; the latest was in July 2026.

Total deals
47
Market trades
37
Secondary share transfers
4
Funding rounds
3
Rights issues
2
Disclosed funding
₹460 Cr

Deals on record (5 of 47)

WhenDealAmountParties
Jun 2025Market trade₹99 CrBuyer: Pronomz Ventures LLP
Seller: Spiracca Ventures LLP
Jun 2024Market trade₹99 CrBuyer: Authum Investment & Infrastructure Limited
Seller: Tpg Growth Iv Sf Pte Ltd
Apr 2024Market trade₹57.58 CrBuyer: Graviton Research Capital LLP , Hrti Private Limited , Qe Securities LLP
Seller: Graviton Research Capital LLP , Hrti Private Limited , Qe Securities LLP
Apr 2024Market trade₹56.63 CrBuyer: Graviton Research Capital LLP , Microcurves Trading Private Limited , Qe Securities LLP
Seller: Graviton Research Capital LLP , Microcurves Trading Private Limited , Qe Securities LLP
Apr 2024Market trade₹21.64 CrBuyer: Graviton Research Capital LLP , Qe Securities LLP
Seller: Graviton Research Capital LLP , Qe Securities LLP

To see the full deal history of Solara Active Pharma Sciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Solara Active Pharma Sciences Limited was last rated by Crisil on 24 Sep 2020.

Rating agencyRated onRating
Crisil24 Sep 2020

To see the full credit ratings and regulatory alerts of Solara Active Pharma Sciences Limited, buy the company report.

MSME payment delays

Solara Active Pharma Sciences Limited has 3 MSME Form 1 returns on record between 2019 and 2022, listing 43 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 12)

SupplierAmount dueDue sinceReported on
RXN Chemicals Private Limited
an individual supplier
Siflon Polymers Pvt Ltd
Aditya Better Containers Pvt. Ltd.,
Rolon Seals

To see the full MSME payment records of Solara Active Pharma Sciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Solara Active Pharma Sciences has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Sequent Penems Private LimitedU24233KA2010PTC053548
Chemsynth Laboratories Private LimitedU24297TG2009PTC064991

To see the full group structure of Solara Active Pharma Sciences Limited, buy the company report.

Employees & EPFO

Solara Active Pharma Sciences Limited has a workforce of 1,656 employees on its EPFO records as of Mar 25, 2024, across 7 active EPFO establishments.

Employee count
1,656
Active EPFO establishments
7
Employee growth
6.29%

GST

Solara Active Pharma Sciences has 8 GST registrations: 6 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
8
Active
6
Cancelled / inactive
2
GSTINStateStatusRegistered on
27AAYCS2093N2ZBMaharashtraActive30 Dec 2019
29AAYCS2093N1Z8KarnatakaActive16 Nov 2017
33AAYCS2093N1ZJTamil NaduActive14 Mar 2018
34AAYCS2093N1ZHPuducherryActive26 Mar 2018

To see the full GST registrations and return filing status of Solara Active Pharma Sciences Limited, buy the company report.

Recent activity

Solara Active Pharma Sciences Limited has 42 board changes on record since 2017: 26 appointments and 16 cessations. The latest: Sanjeevi Mohanraj was appointed as Whole-Time Director on 01 Jan 2026.

Charges
A charge registered on 21 Jan 2021 via Charge ID 100413686 with Others was fully satisfied on 11 May 2026.
Filing
Solara Active Pharma Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge with Others of Rs. 142.50 Cr registered on 30 May 2019 with Charge ID 100268311 was modified on 05 Feb 2026.
Charges
A charge with Others of Rs. 75.00 Cr registered on 30 Jan 2025 with Charge ID 101045752 was modified on 14 Jan 2026.
Appointed
Sanjeevi Mohanraj was appointed as Whole-Time Director.
Ceased
Kartheek Chintalapati Raju ceased to be Director.
AGM
Solara Active Pharma Sciences Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Appointed
Sarat Kumar Asuri was appointed as CFO.
Ceased
Poorvank Purohit ceased to be Managing Director.
Appointed
Sandeep Shashikantha Rao was appointed as Managing Director.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101045752 was registered on 30 Jan 2025.
Ceased
Ankur Nand Thadani ceased to be Director.

87 earlier events are in the company report.

News

SOLARA: Q2 CONS NET PROFIT 285M RUPEES VS LOSS 101M (YOY)
16 Oct 2026 · Exchange Update
SOLARA: Q2 REVENUE 4.2B RUPEES VS 3.14B (YOY)
16 Oct 2026 · Exchange Update
SOLARA: Q2 EBITDA 771M RUPEES VS 347.3M (YOY); Q2 EBITDA MARGIN 18.25% VS 11.08% (YOY)
16 Oct 2026 · Exchange Update

Frequently asked questions

Solara Active Pharma Sciences is an active public limited company based in Thane, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 23 February 2017 (9+ years old) and is registered under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA.

Solara Active Pharma Sciences reported revenue of ₹1,368.98 Cr for FY 2025-26 (up 6.6% YoY) based on consolidated financials.

Solara Active Pharma Sciences has 8 current directors:

The latest financial statements of Solara Active Pharma Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from FY 2017 are in the company report.

The GSTIN of Solara Active Pharma Sciences is 27AAYCS2093N2ZB, registered in Maharashtra. The company has 8 GST registrations in all, of which 6 are active and 2 are cancelled or inactive. Other active GSTINs include 29AAYCS2093N1Z8 (Karnataka), 33AAYCS2093N1ZJ (Tamil Nadu), 34AAYCS2093N1ZH (Puducherry).

The CIN (Corporate Identification Number) of Solara Active Pharma Sciences is L24230MH2017PLC291636. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Solara Active Pharma Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 541540) and NSE (symbol: SOLARA).

Solara Active Pharma Sciences has 37 court cases on record: 19 filed by the company and 18 filed against it. 14 are pending. Most are in the district courts.

Solara Active Pharma Sciences was incorporated on 23 February 2017, making it 9+ years old. It is registered with the Registrar of Companies, Mumbai.

Solara Active Pharma Sciences has 47 deals on record (37 market trades, 4 secondary share transfers, 3 funding rounds), with disclosed funding of ₹460 Cr; the latest was in July 2026.

Sanjeevi Mohanraj was appointed as Whole-Time Director on 01 Jan 2026. Kartheek Chintalapati Raju ceased to be Director on 05 Nov 2025. Sarat Kumar Asuri was appointed as CFO on 02 Apr 2025. Solara Active Pharma Sciences has 42 board changes on record in total.